Medicine Pharmaceuticalsanticancer drug
• Subcutaneous long-acting octreotide • Fast onset and one month duration of therapeutic plasma-levels • Provided ready-for-use in prefilled syringes for easy self-administration • Compatible with autoinjectors • High bioavailability – 500% higher than Sandostatin® LAR®, with potential for better treatment effects in some patients • Easy and convenient administration • Improved treatment adherence • Adapted to prefilled syringes and autoinjectors • Long-acting drug release • Small injection volume with a thin needle • Good safety profile • Manufacturing by standard processes
CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus’ proprietary FluidCrystal® injection depot technology. It is provided as a prefilled syringe, thus not requiring any reconstitution or conditioning prior to administration. Due to the superior ease of handling and administration, CAM2029 can be conveniently administered by the patients’ themselves.
Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines.
Camurus’ FluidCrystal® injection depot is designed to provide treatment efficacy over extended periods – from days to months – with a single injection. It has the potential to reduce the burden of daily medication while increasing adherence to therapy. FluidCrystal® is suitable for biological peptides as well as small molecules.
The FluidCrystal® injection depot comprises a lipid-based liquid with a dissolved active ingredient that can easily be injected subcutaneously using a conventional syringe with a thin needle. Upon contact with fluids in the tissue, the lipid solution transforms into a liquid crystalline gel, which effectively encapsulates the active ingredient. The drug compound is slowly released as the liquid crystalline matrix gradually degrade in the tissue and the release can be controlled from several days to weeks or months depending on the composition. The system’s simplicity, including a spontaneous self-association to a functional structure in the body, eliminates complicated manufacturing procedures and the need for mixing prior to administration. Medicines based on the FluidCrystal® injection depot has the potential to be administered by the patients themselves or by healthcare professionals, without time-consuming and complicated reconstitution procedures. The long-acting drug release aims to reduce the patient’s burden of administering medication daily, improve the adherence to and results of the treatment, and improve the patient’s quality of life.